Riding China’s Oncology Market: ‘Verticalization’ Best?
While there have been a number of positive changes in the operating and regulatory environment in China, pharmaceutical companies will still need a focused strategy to succeed in the country’s increasingly competitive but potentially lucrative oncology market, according to one expert.
You may also be interested in...
As the traditional lines between therapeutics and diagnostics become increasingly blurred, genomic testing is growing apace in China, boosted by the country’s national push into precision medicine. Deals and alliances are coming thick and fast as companies jostle for a slice of the growing pie.
Suzhou-based Innovent Bio becomes the fourth biotech from mainland China to go public in Hong Kong, and its strong first-day performance may have given the seemingly spooked market so far for such companies a shot of confidence.
A rapidly reforming policy and regulatory environment and a growing culture of innovation are encouraging capital and talent to pour into China, making it a question of when, rather than if, the payoffs will come for both consumers and investors.